Wall Street brokerages expect that ArQule, Inc. (NASDAQ:ARQL) will report earnings per share of ($0.11) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for ArQule’s earnings. ArQule posted earnings per share of ($0.07) in the same quarter last year, which would indicate a negative year-over-year growth rate of 57.1%. The company is scheduled to report its next earnings report before the market opens on Friday, August 4th.

On average, analysts expect that ArQule will report full year earnings of ($0.45) per share for the current year. For the next financial year, analysts anticipate that the business will report earnings of ($0.40) per share. Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover ArQule.

ArQule (NASDAQ:ARQL) last posted its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.11) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.11). ArQule had a negative return on equity of 95.33% and a negative net margin of 482.44%. During the same period in the prior year, the company posted ($0.08) EPS.

Separately, Zacks Investment Research cut shares of ArQule from a “hold” rating to a “sell” rating in a research note on Thursday, May 4th.

An institutional investor recently raised its position in ArQule stock. Renaissance Technologies LLC increased its stake in shares of ArQule, Inc. (NASDAQ:ARQL) by 1.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,017,600 shares of the biotechnology company’s stock after buying an additional 26,900 shares during the period. Renaissance Technologies LLC owned 2.84% of ArQule worth $2,542,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 60.55% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/07/25/arqule-inc-arql-expected-to-announce-earnings-of-0-11-per-share.html.

ArQule (NASDAQ ARQL) traded up 1.63% on Tuesday, hitting $1.25. The stock had a trading volume of 29,926 shares. The company’s 50 day moving average is $1.21 and its 200-day moving average is $1.22. The firm’s market capitalization is $88.93 million. ArQule has a 1-year low of $0.92 and a 1-year high of $1.82.

ArQule Company Profile

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Get a free copy of the Zacks research report on ArQule (ARQL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.